Please login to the form below

Not currently logged in
Email:
Password:

tau

This page shows the latest tau news and features for those working in and with pharma, biotech and healthcare.

AmyPore gets EU backing for Alzheimer’s and Parkinson’s therapy

AmyPore gets EU backing for Alzheimer’s and Parkinson’s therapy

mechanism to the long list of amyloid- and tau-targeting drugs that have so far comprehensively failed to show any significant benefit in neurodegenerative disorders, including most recently Biogen’s aducanumab.

Latest news

More from news
Approximately 3 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    disease. Targeting tau. Tau is among the beneficiaries of the broader focus and emerging interest in combination therapies. ... Abeta plaques and neurofibrillary tangles of tau proteins are the two main pathological features.

  • Deal Watch January 2018

    Under this transaction Takeda gains options to three Denali programmes for neurodegenerative disorders: the ATV: BACE1/Tau and ATV: TREM2 programmes, which are both at preclinical stage for Alzheimer's disease, ... Acquisition company. 4, 800. Denali

  • Deal Watch - May 2017 Deal Watch - May 2017

    BMS. Biogen (US). Licence. Anti-tau antibody pre phase 2 for  progressive supranuclear palsy.

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    He believes that “tau has received nothing like the attention that amyloid has by big pharma - they all jump on the bandwagon, unfortunately. ... There are studies progressing with tau as a target, but it will be a while before clear evidence emerges.

  • Pharma deals in May 2015 Pharma deals in May 2015

    1, 100. Sigma Tau/ Baxter. Asset acquisition. Oncaspar (pegasparagase - marketed) portfolio in acute lymphoblastic leukaemia (ALL).

More from intelligence
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Pharma industry appointments Pharma industry appointments

    Lemus was also chief executive officer of Sigma Tau Pharmaceuticals and chief financial officer and executive vice president of MorphoSys, where he took the company public in 1999.

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    Ryan brings over 15 years of central nervous system clinical research experience to the role, and takes on responsibility for Asceneuron's pipeline of innovative small molecules and progressing tau modifiers ... His outstanding track record and expertise

  • Nanobiotix strengthens US leadership team Nanobiotix strengthens US leadership team

    He has also served as vice president and head of clinical development oncology at MannKind, and held clinical leadership positions at MedImmune and Sigma-Tau Research.

  • Sigma-Tau Pharmaceuticals appoints CEO Sigma-Tau Pharmaceuticals appoints CEO

    Rare disease specialist Sigma-Tau Pharmaceuticals has appointed Michael Minarich as chief executive officer. ... Prior to joining Sigma-Tau, Micharich was the Pharmacia Corporation's market company president in the Czech Republic and oversaw the merger

  • EMA names new head of legal service EMA names new head of legal service

    An Italian national, Marino has extensive legal experience in the pahrma industry, having served as director of corporate legal and intellectual property at pharma firm Sigma-Tau since 1997.

More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Forecasting in Forgotten Markets

    From a scientific perspective, the jury is still out on the root cause of these conditions and whether the current hypothesis around the involvement of Amyloid and Tau proteins in different

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics